Literature DB >> 31493211

Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer.

Si Gao1,2, Siyao Du1,2, Zaiming Lu1,2, Jun Xin1, Song Gao3, Hongzan Sun4,5.   

Abstract

OBJECTIVES: To assess the value of 18F-FDG PET and MR-IVIM parameters before and during concurrent chemoradiotherapy (CCRT) for evaluating early treatment response and predicting tumor recurrence in patients with locally advanced cervical cancer (LACC) using a hybrid PET/MR scanner.
METHODS: Fifty-one patients with LACC underwent pelvic PET/MR scans with an IVIM sequence at two time-points (pretreatment [pre] and midtreatment [mid]). Pre- and mid-PET parameters (SUVmax, MTV, TLG) and IVIM parameters (D, F, D*) and their percentage changes (Δ%SUVmax, Δ%MTV, Δ%TLG, Δ%D, Δ%F, Δ%D*) were calculated. We selected independent imaging parameters and built a combined prediction model incorporating imaging parameters and clinicopathological risk factors. The performance of the combinative evaluation for tumor early shrinkage rates (TESR) and the prediction model for tumor recurrence was assessed.
RESULTS: Thirty-two patients were classified into the good response (GR) group with TESR ≥ 50%, and 19 patients were categorized into the poor response (PR) group with TESR < 50%. Δ%D (p = 0.013) and Δ%F (p = 0.006) are independently related to TESR with superior combined diagnostic ability (AUC = 0.901). Pre-TLG, Δ%D, and suspicious lymph node metastasis (SLNM) were selected for the construction of the combined prediction model. The model for identifying the patients with high risk of tumor recurrence reached a moderate predictive ability and good stability with c-index of 0.764 (95% CI, 0.672-0.855).
CONCLUSION: The combined prediction model based on pretreatment PET metabolic parameter (pre-TLG), IVIM-D percentage changes, and LNs status provides great potential to identify the LACC patients with high risk of recurrence at early stage of CCRT. KEY POINTS: • PET/MR plus IVIM offers various complementary information for LACC. • IVIM-D and IVIM-F percentage changes are independently related to tumor early shrinkage rates. • The combined prediction model can help identify the LACC patients with high risk of tumor recurrence.

Entities:  

Keywords:  Cervical cancer; Concurrent chemoradiotherapy; Diffusion magnetic resonance imaging; Positron emission tomography

Mesh:

Substances:

Year:  2019        PMID: 31493211     DOI: 10.1007/s00330-019-06428-w

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  23 in total

1.  Role of conventional and diffusion weighted MRI in predicting treatment response after low dose radiation and chemotherapy in locally advanced carcinoma cervix.

Authors:  Saikat Das; Anuradha Chandramohan; Jeba Karunya Rami Reddy; Sramana Mukhopadhyay; Ramani Manoj Kumar; Rajesh Isiah; Subhashini John; Regi Oommen; Visalakshi Jeyaseelan
Journal:  Radiother Oncol       Date:  2015-10-20       Impact factor: 6.280

Review 2.  Locally advanced cervical cancer: what is the standard of care?

Authors:  Zeina Al-Mansour; Claire Verschraegen
Journal:  Curr Opin Oncol       Date:  2010-09       Impact factor: 3.645

3.  Can diffusion-weighted magnetic resonance imaging predict tumor recurrence of uterine cervical cancer after concurrent chemoradiotherapy?

Authors:  Jung Min Bae; Chan Kyo Kim; Jung Jae Park; Byung Kwan Park
Journal:  Abdom Radiol (NY)       Date:  2016-08

4.  Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging.

Authors:  D Le Bihan; E Breton; D Lallemand; M L Aubin; J Vignaud; M Laval-Jeantet
Journal:  Radiology       Date:  1988-08       Impact factor: 11.105

5.  Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer?

Authors:  Burcu Esen Akkas; Busra Bedriye Demirel; Aysen Dizman; Gulin Ucmak Vural
Journal:  Ann Nucl Med       Date:  2013-06-21       Impact factor: 2.668

6.  Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results.

Authors:  Johannes Grueneisen; Benedikt Michael Schaarschmidt; Martin Heubner; Bahriye Aktas; Sonja Kinner; Michael Forsting; Thomas Lauenstein; Verena Ruhlmann; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-22       Impact factor: 9.236

Review 7.  A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer.

Authors:  John M Kirwan; Paul Symonds; John A Green; Jayne Tierney; Mandy Collingwood; Christopher J Williams
Journal:  Radiother Oncol       Date:  2003-09       Impact factor: 6.280

8.  Predicting and Early Monitoring Treatment Efficiency of Cervical Cancer Under Concurrent Chemoradiotherapy by Intravoxel Incoherent Motion Magnetic Resonance Imaging.

Authors:  Li Zhu; Lijing Zhu; Huanhuan Wang; Jing Yan; Baorui Liu; Weibo Chen; Jian He; Zhengyang Zhou; Xiaofeng Yang
Journal:  J Comput Assist Tomogr       Date:  2017 May/Jun       Impact factor: 1.826

Review 9.  Functional imaging to predict tumor response in locally advanced cervical cancer.

Authors:  Tara D Barwick; Alexandra Taylor; Andrea Rockall
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

10.  Predictive and prognostic value of intravoxel incoherent motion (IVIM) MR imaging in patients with advanced cervical cancers undergoing concurrent chemo-radiotherapy.

Authors:  Li Zhu; Huanhuan Wang; Lijing Zhu; Jie Meng; Yan Xu; Baorui Liu; Weibo Chen; Jian He; Zhengyang Zhou; Xiaofeng Yang
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

View more
  7 in total

1.  Imaging Biomarkers and Liquid Biopsy in Assessment of Cervical Cancer.

Authors:  Mansur A Ghani; Joy Liau; Ramez Eskander; Loren Mell; Tahir Yusufaly; Sebastian Obrzut
Journal:  J Comput Assist Tomogr       Date:  2022-08-16       Impact factor: 2.081

2.  Application of integrated positron emission tomography/magnetic resonance imaging in evaluating the prognostic factors of head and neck squamous cell carcinoma with positron emission tomography, diffusion-weighted imaging, dynamic contrast enhancement and combined model.

Authors:  Haodan Dang; Yu Chen; Zhuhua Zhang; Xiaohua Shi; Xingming Chen; Xiaoli Zhu; Bo Hou; Haiqun Xing; Huadan Xue; Zhengyu Jin
Journal:  Dentomaxillofac Radiol       Date:  2020-04-03       Impact factor: 2.419

3.  Predictive value of clinical and 18F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma.

Authors:  Lisa Marr; Bernhard Haller; Thomas Pyka; Jan C Peeken; Moritz Jesinghaus; Klemens Scheidhauer; Helmut Friess; Stephanie E Combs; Stefan Münch
Journal:  Sci Rep       Date:  2022-05-03       Impact factor: 4.379

4.  Quantitative PET Imaging and Clinical Parameters as Predictive Factors for Patients With Cervical Carcinoma: Implications of a Prediction Model Generated Using Multi-Objective Support Vector Machine Learning.

Authors:  Zhiguo Zhou; Genevieve M Maquilan; Kimberly Thomas; Jason Wachsmann; Jing Wang; Michael R Folkert; Kevin Albuquerque
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 5.  Quantitative Magnetic Resonance Imaging for Biological Image-Guided Adaptive Radiotherapy.

Authors:  Petra J van Houdt; Yingli Yang; Uulke A van der Heide
Journal:  Front Oncol       Date:  2021-01-29       Impact factor: 6.244

6.  Application of Field-of-View Optimized and Constrained Undistorted Single Shot (FOCUS) with Intravoxel Incoherent Motion (IVIM) in 3T in Locally Advanced Rectal Cancer.

Authors:  Yipeng Cheng; Huijie Jiang; Hui Wang; Qingchao Tang; Tianyi Liu
Journal:  Dis Markers       Date:  2021-03-20       Impact factor: 3.434

7.  Combining Intravoxel Incoherent Motion Diffusion Weighted Imaging and Texture Analysis for a Nomogram to Predict Early Treatment Response to Concurrent Chemoradiotherapy in Cervical Cancer Patients.

Authors:  Xiaomin Zheng; Cuiping Li; Lufeng Zhang; Feng Cao; Xin Fang; Liting Qian; Jiangning Dong
Journal:  J Oncol       Date:  2021-12-24       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.